



# Influenza Situation Report: 2015-2016 Season

Department of the Navy

Week 14 (3 April to 9 April 2016)

## Overall Summary

The number of laboratory positive cases and antiviral prescriptions remain above seasonal baselines, but appear to have peaked and continue to decrease. The rates of influenza cases among children remain above baseline.

## Key Findings

### Influenza Activity and Surveillance

#### Laboratory

80 laboratory positive influenza cases were identified during Week 14, slightly above baseline.



[Details](#)

#### Antivirals (AVs)

127 AV medications were dispensed in Week 14, slightly above baseline. [Details](#)

#### Influenza-Like Illness (ILI)

Overall, 3.9% of outpatient medical encounters were due to ILI, comparable to baseline. [Details](#)



### Severity Indicators

#### Inpatient

This week, there were four inpatient laboratory positive cases and seven inpatient antiviral prescriptions. No influenza case reports were identified in DRSi. [Details](#)

#### Coinfections

There were seven bacterial coinfections identified among laboratory positive cases during Week 14. [Details](#)

### Select Populations

#### Active Duty and Recruits

In Week 14, there were ten laboratory positive cases and 21 AV prescriptions dispensed to active duty personnel. Among recruits, there were two laboratory positive cases and one AV prescription. [Details](#)

NHRC surveillance reports febrile respiratory illness rates were at or below expected values at MCRD San Diego, MCRD Parris Island and NRTC Great Lakes for Week 13. [Details](#)

#### Children

Influenza positive laboratory cases and AV prescriptions among children were above baseline. [Details](#)

### Active Duty Vaccination Rates

Navy: 95.1%  
Marine Corps: 96.5%  
US Fleet Forces: 99.2%

[View Table](#)

Data source: MRRS, current as of 11 Apr 2016.

Prepared by the EpiData Center ([email](#); [web](#))





# Influenza Activity and Surveillance

## Overall Burden


The estimated burden of influenza across the DON combines three major sources of data: certified laboratory results, antiviral pharmacy transactions, and medical encounters with influenza-specific diagnoses.

- During Week 14, there were 184 DON cases identified in one or more data sources; pharmacy captured the highest proportion of cases (69.0%). Seventeen cases were identified in all three sources.
- Since Week 40, there have been 5,730 DON cases identified in at least one of the three data sources.




## Laboratory Cases

- 80 laboratory positive influenza cases were identified during Week 14 (51 type A, 25 type B, 4 type A & B,); slightly above baseline.
  - Top three facilities this week: NH Jacksonville (13), NH Camp Lejeune (13), NMC San Diego (9).
- Since Week 40, 2,028 laboratory positive cases were identified among DON beneficiaries. Top three facilities thus far: NMC San Diego (428), NH Jacksonville (205), NH Camp Pendleton (162).



## Specimen Positivity

- 15.4% of all influenza specimens tested during Week 14 were positive, exceeding the percentage for the same time last season (9.3%).
- When grouped by parent facility, 13 locations (46.4%) tested more than ten specimens. The facilities with the highest specimen positivity were NHC Hawaii (38.5%) and NH Jacksonville (31.0%).




Test Types among Positive Influenza Specimens, n (%)				
	Rapid	Culture	PCR	Total
<b>Week 12</b>	93 (62.0)	25(16.7)	32 (21.3)	150
<b>Week 13</b>	96 (64.4)	20(13.4)	33 (22.1)	149
<b>Week 14</b>	61(72.6)	5 (6.0)	18 (21.4)	84
<b>Season</b>	1,296 (58.2)	230 (10.3)	702(31.5)	2,228

## Antiviral Prescriptions

- 127 antiviral prescriptions (126 oseltamivir, 1 amantadine) were dispensed during Week 14. AV prescriptions remain above baseline, with a continuing declining trend.
- Top three facilities this week: NMC San Diego (18), NH Camp Lejeune (15), NH Jacksonville (13).
- Since Week 40, the majority (99.2%) of prescriptions were for oseltamivir.

Antiviral Medications Dispensed to DON Beneficiaries, n (%)					
	Amantadine	Oseltamivir	Rimantadine	Zanamivir	Total
<b>Week 14</b>	1(0.8)	126 (99.2)	0 (0.0)	0 (0.0)	127
<b>Season</b>	28 (0.8)	3,615 (99.2)	0 (0.0)	0 (0.0)	3,643




[< Back to Key Findings](#)



# Syndromic Surveillance

## Influenza-Like Illness (ILI)


- The percent of medical encounters that included an ILI diagnosis during Week 13 (lagged due to data availability):
  - 3.9% of outpatient encounters (comparable to baseline)
  - 12.2% of ER admissions (below baseline)
- When grouped by parent facility, 9 DON facilities (32.1%) experienced an increase in the proportion of outpatient ILI visits during Week 13. None experienced an increase above 25%; NH Beaufort (23.1%) experienced the highest increase.



## Severity Indicators


### Inpatient Laboratory

- Four influenza positive laboratory cases (5.0% of all laboratory cases) were identified in the inpatient setting during Week 14.
- This week's cases were four retirees (2 Navy and 2 Marine Corps) ages 45+ at NMC San Diego (3) and 673rd Med Grp-Elmendorf (1). All four cases were type A positive.



### Inpatient Pharmacy

- Seven influenza AVs (5.5% of all influenza AVs) were prescribed in the inpatient setting during Week 14, below baseline (6.4%).
- NMC San Diego dispensed three AVs in the inpatient setting, and four other facilities dispensed one AV each. This week's AVs were dispensed to non-active duty sponsors (4), a spouse, an active duty service member, and a non-sponsor.



### Influenza-Associated Hospitalization Reports

- No influenza cases were reported to DRSi during Week 14.

## Bacterial Coinfections

- There were seven coinfections identified during Week 14. The coinfections consisted of 2 upper respiratory (both *Streptococcus*), 1 lower respiratory (*Klebsiella*) and 4 non-respiratory infections.
- Overall coinfection case counts remain below baseline. [Details](#)

Proportion Bacterial Coinfections by Respiratory Source and Percent of Laboratory Positive Cases with a Bacterial Coinfections since Week 40, 2015-2016 Season				
	Coinfections by Respiratory Source, n (%)			Lab Cases with Bacterial Coinfection (%)
	Upper Respiratory	Lower Respiratory	Non-Respiratory	
<b>Current Season (n=90)</b>	34 (37.8)	12 (13.3)	44 (48.9)	4.4
<b>Cumulative Baseline (n=99.8)</b>	38 (38.1)	8.5 (8.5)	53.3 (53.4)	3.8

\* Cumulative baseline calculated as a weighted average over three years and may not represent whole numbers.


[< Back to Key Findings](#)



# Select Populations

## Active Duty

- Ten laboratory positive influenza cases were identified among active duty Navy (9) and Marine Corps (1) service members during Week 14 (5 type A and 5 type B). Top facilities this week: NH Yokosuka (2) and NH Camp Lejeune (2).
- 21 active duty service members (16 Navy, 5 Marines) were dispensed AVs (20 oseltamivir, 1 amantadine) during Week 14.



## Recruits

- Two laboratory positive influenza cases (type A positive) were identified among Navy recruits during Week 14. Both cases were identified at James A Lovell FHCC.
- One AVs was dispensed to a recruit during Week 14 at James A Lovell FHCC.



Status	Immunity Status	Vaccine Type				Total	Percent
		LAV	IV	LAV & IV	None		
Active Duty	Vaccinated, immune	71	134	5	-	210	80.2%
	Vaccinated, not immune	7	11	-	-	18	6.9%
	No vaccination record	-	-	-	34	34	13.0%
<b>Total</b>		<b>78</b>	<b>145</b>	<b>5</b>	<b>-</b>	<b>262</b>	<b>-</b>
Recruit	Vaccinated, immune	22	23	-	-	45	63.4%
	Vaccinated, not immune	18	8	-	-	26	36.6%
	Total	40	31	-	-	71	-

(LAV)Live-attenuated influenza vaccine (intranasal), (IV)Inactivated influenza vaccine (injection)  
Vaccinated, immune: Vaccinated more than 14 days prior to infection

Number of DON Active Duty and Recruit Cases since Week 40, 2015-2016 Season					
Case Type	Active Duty		Recruits		Total
	Navy	Marine Corps	Navy	Marine Corps	
Laboratory Positive	197	65	50	21	333
AV Prescriptions	463	159	9	91	722

## Children

- The rate of laboratory positive influenza cases (per 100,000) among children was 11.2 for ages 0-4 years and 7.0 for ages 5-17.
- 34 laboratory positive influenza cases were identified among children during Week 14, less than one standard deviation above baseline.
  - There were 14 cases among children ages 0-4 and 20 among children ages 5-17.
- The rate of AV prescriptions (per 100,000) is highest among children 0-4 years (5.3) followed by children 5-17 years (2.3).
- There were 48 AVs dispensed to children during Week 14, more than double baseline estimates.
  - This week's cases (all oseltamivir) include 24 children ages 0-4 years old and 24 children ages 5-17 years old. NH Camp Lejeune (7) dispensed the most AVs. No AVs were dispensed in the inpatient setting.



## In the News

- Flu activity continues to decrease but remains elevated in the United States. [Details](#)
- Flu reports remain elevated but have likely peaked in North America and Europe [Details](#)

[< Back to Key Findings](#)

